JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB98535

Goat F(ab')2 Anti-Human IgG (Fab')2 (HRP)

5

(1 Review)

|

(10 Publications)

Suitable for ICC, IHC-P, ELISA, WB. Ideal for western blot. Cited in 10 publications.

View Alternative Names

Immunoglobulin heavy constant gamma 1, Ig gamma-1 chain C region, Ig gamma-1 chain C region EU, Ig gamma-1 chain C region KOL, Ig gamma-1 chain C region NIE, IGHG1, Immunoglobulin heavy constant gamma 4, Ig gamma-4 chain C region, IGHG4, Immunoglobulin heavy constant gamma 3, HDC, Heavy chain disease protein, Ig gamma-3 chain C region, IGHG3, Immunoglobulin heavy constant gamma 2, Ig gamma-2 chain C region, Ig gamma-2 chain C region DOT, Ig gamma-2 chain C region TIL, Ig gamma-2 chain C region ZIE, IGHG2

Key facts

Host species

Goat

Target species

Human

Target isotype

IgG

Target specificity

F(ab')2

Minimal cross-reactivity
Pre-adsorbed

No

Conjugation

HRP

Excitation/Emission
Applications

WB, IHC-P, ELISA, ICC

applications

Clonality

Polyclonal

Isotype

IgG

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ICC": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "IHC-P": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/200 - 1/2000", "notes":"<p></p>" }, "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/10000 - 1/100000", "notes":"<p>(Primary).</p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"1/2000 - 1/25000", "notes":"<p>(Colorimetric: 1/2000 - 1/20000, Chemiluminescent: 1/5000 - 1/25000).</p>" } } }

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Immunogen
Purification notes
This antibody was isolated by affinity chromatography using antigen coupled to agarose beads. F(ab')2 fragments were generated using a pepsin digestion. Fc fragments and whole IgG molecules have been removed. Fragments were conjugated to Horse Radish Peroxidase.
Storage buffer
pH: 6.8 - 7.4 Preservative: 0.05% CMIT/MIT based preservative Constituents: 0.2% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Product protocols

Target data

Constant region of immunoglobulin (Ig) heavy chains. Igs are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound Igs serve as receptors, which upon binding to a specific antigen trigger the clonal expansion and differentiation of B lymphocytes into Ig-secreting plasma cells. Secreted Igs known as antibodies mediate the effector phase of humoral immunity by blocking the interaction of infectious antigens with cellular receptors (via the antigen-binding region) and eliciting effector mechanisms that lead to pathogen neutralization (via the constant region) (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The antigen-binding region is formed by the variable domain of one heavy chain paired with the variable domain of its associated light chain. Each Ig molecule has two antigen-binding sites with remarkable affinity for a particular antigen due to V-(D)-J rearrangement, somatic hypermutations and affinity maturation of the variable domains upon antigen exposure (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region defines the Ig isotype that perform distinct sets of effector functions. B cells diversify and rearrange their Ig constant regions through class-switch recombination, a process by which the constant region is switched from one Ig isotype to another, namely from IgM and IgD to IgG, IgA and IgE (PubMed : 17576170, PubMed : 20176268, PubMed : 22158414). The constant region of Ig gamma-1 (IgG1) isotype interacts (via the fragment crystallizable, Fc) with receptors on innate immune cells and the complement system to mediate humoral effector functions, including antibody-dependent cellular cytotoxicity or phagocytosis, complement-dependent cytotoxicity and inflammatory responses.
See full target information IGHG1

Additional targets

IGHG3,IGHG4,IGHG2

Publications (10)

Recent publications for all applications. Explore the full list and refine your search

iScience 25:105202 PubMed36168391

2022

Asymptomatic or symptomatic SARS-CoV-2 infection plus vaccination confers increased adaptive immunity to variants of concern.

Applications

Unspecified application

Species

Unspecified reactive species

Peifang Sun,Irene Ramos,Camila H Coelho,Alba Grifoni,Corey A Balinsky,Sindhu Vangeti,Alison Tarke,Nathaniel I Bloom,Vihasi Jani,Silvia J Jakubski,David A Boulifard,Elizabeth Cooper,Carl W Goforth,Jan Marayag,Amethyst Marrone,Edgar Nunez,Lindsey White,Chad K Porter,Victor A Sugiharto,Megan Schilling,Avinash S Mahajan,Charmagne Beckett,Alessandro Sette,Stuart C Sealfon,Shane Crotty,Andrew G Letizia

International journal of molecular sciences 22: PubMed34445266

2021

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis.

Applications

Unspecified application

Species

Unspecified reactive species

Margherita Passariello,Cinzia Vetrei,Felice Amato,Claudia De Lorenzo

Scientific reports 11:11046 PubMed34040046

2021

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.

Applications

Unspecified application

Species

Unspecified reactive species

Margherita Passariello,Chiara Gentile,Veronica Ferrucci,Emanuele Sasso,Cinzia Vetrei,Giovanna Fusco,Maurizio Viscardi,Sergio Brandi,Pellegrino Cerino,Nicola Zambrano,Massimo Zollo,Claudia De Lorenzo

Vox sanguinis 116:106-115 PubMed32770852

2020

Slot blotting and flow cytometry: two efficient assays for platelet antibody screening among patients with platelet refractoriness.

Applications

Unspecified application

Species

Unspecified reactive species

Zahra Ameri,Reza Vahidi,Morteza Khaleghi,Tania Dehesh,Amir Sheikhbardsiri,Alireza Farsinejad

Cancers 12: PubMed32781690

2020

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells.

Applications

Unspecified application

Species

Unspecified reactive species

Margherita Passariello,Cinzia Vetrei,Emanuele Sasso,Guendalina Froechlich,Chiara Gentile,Anna Morena D'Alise,Nicola Zambrano,Elisa Scarselli,Alfredo Nicosia,Claudia De Lorenzo

Heliyon 6:e04114 PubMed32551380

2020

Rapid and specific detection of oxidized LDL/β2GPI complexes via facile lateral flow immunoassay.

Applications

Unspecified application

Species

Unspecified reactive species

Xian Wen Tan,Fumiaki Takenaka,Hironori Takekawa,Eiji Mastuura

Structure (London, England : 1993) 28:897-909.e6 PubMed32433992

2020

Networks of HIV-1 Envelope Glycans Maintain Antibody Epitopes in the Face of Glycan Additions and Deletions.

Applications

Unspecified application

Species

Unspecified reactive species

Gemma E Seabright,Christopher A Cottrell,Marit J van Gils,Alessio D'addabbo,David J Harvey,Anna-Janina Behrens,Joel D Allen,Yasunori Watanabe,Nicole Scaringi,Thomas M Polveroni,Allison Maker,Snezana Vasiljevic,Natalia de Val,Rogier W Sanders,Andrew B Ward,Max Crispin

Scientific reports 9:13125 PubMed31511565

2019

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.

Applications

Unspecified application

Species

Unspecified reactive species

Margherita Passariello,Anna Morena D'Alise,Annachiara Esposito,Cinzia Vetrei,Guendalina Froechlich,Elisa Scarselli,Alfredo Nicosia,Claudia De Lorenzo

mAbs 10:1060-1072 PubMed29995563

2018

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Emanuele Sasso,Chiara D'Avino,Margherita Passariello,Anna Morena D'Alise,Daniela Siciliano,Maria Luisa Esposito,Guendalina Froechlich,Riccardo Cortese,Elisa Scarselli,Nicola Zambrano,Alfredo Nicosia,Claudia De Lorenzo

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 18:2763-2771 PubMed29603642

2018

Xenoreactive antibodies and latent fibrin formation in VAD and cardiac transplant recipients can confound the detection and measurement of anti-AT1R antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Martin Oaks,Karen Michel,Francis X Downey,Vinay Thohan
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com